Empagliflozin/Metformin Tablets 12.5/500 mg

Adult dose

The recommended dosage of this medication is 1 tablet at a time, twice a day. The maximum daily recommended dosages for each ingredient should not exceed 25 mg of empagliflozin and 2000 mg of metformin. For patients who struggle to control blood sugar with metformin alone or in combination with other medications such as insulin, the recommended dosage is 5 mg of empagliflozin twice a day (total 10 mg) along with the usual dosing of metformin. If tolerance is good and additional blood sugar control is needed,

This medication may cause severe lactic acidosis and should not be used in patients with impaired kidney function or those with serious infections, dehydration, heart problems, etc. Caution should be taken as there is a risk of hypoglycemia when used together with other diabetes medications such as insulin or sulfonylureas. Patients with moderate to severe decreased kidney function, acute kidney issues, severe heart failure, or those scheduled for surgery should not take this medication. This medication should not be administered to pregnant or breastfeeding women, nor to patients with impaired liver function. There may be side effects associated with decreased fluid volume, so patients in a dehydrated state or who are at risk of fluid loss should be cautious. Regular kidney function tests should be performed before and during treatment, and careful management is particularly needed for elderly patients or those with diminished kidney function. Urinary tract infections or reproductive infections may occur, so patients should consult their healthcare provider immediately if infection symptoms develop. Vitamin B12 deficiency may occur, thus regular blood tests are recommended for long-term users. Alcohol intake may increase the risk of lactic acidosis, hence excessive drinking should be avoided while taking this medication. While taking this medication, it is important to maintain a regular diet and exercise regimen for blood sugar control, and to respond immediately to hypoglycemic symptoms. If surgery or contrast examinations are planned, this medication should be discontinued for a period and resumed only after kidney function recovery. This medication is not recommended for children under 18 years old, and elderly patients should adjust dosages based on kidney function. Adverse reactions reported include hypoglycemia, gastrointestinal disturbances, urinary and reproductive infections, increased urination, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, abnormal liver function tests, hepatitis, altered taste, rashes, erythema, itching, increased serum lipids, increased serum creatinine, reduced glomerular filtration rate, increased serum creatinine, increased serum creatinine, increased serum creatinine, increased serum creatinine, headache, dizziness, insomnia, constipation, dyspepsia, anxiety,

Serious side effects

Hives, angioedema, severe swelling, perineal necrosis, ketoacidosis, lactic acidosis, severe allergic reactions, severe skin adverse reactions, difficulty breathing, asthma attacks, respiratory abnormalities accompanied by cough and fever, yellowing of the skin or eyes (jaundice), serious neurological symptoms (headaches, lightning headaches, seizures, altered consciousness, visual disturbances, paralysis), significantly reduced urine output, severe swelling or urinary abnormalities, cerebral infarction, myocardial infarction.

Mild side effects

• Hypoglycemia
• urinary tract infection
• reproductive infection
• increased urination
• nausea
• vomiting
• diarrhea
• abdominal pain
• loss of appetite
• constipation

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, the storage temperature should be maintained between 1 and 30 degrees Celsius.

Appearance

Thin brownish purple, biconvex, oval film-coated tablet

Package unit

10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6), 60 tablets/bottle